http://orcid.org/0000-0002-5415-1045
References
- Saint-Laurent Thibault C, Moorjaney D, Ganz ML, et al. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. J Med Econ 2017;20:692-702
- Centers for Disease Control and Prevention. US 2014 surveillance data for viral hepatitis, surveillance for viral hepatitis, statistics and surveillance, 2014. https://www.cdc.gov/hepatitis/statistics/2014surveillance/index.htm, accessed in April 2015
- McGarry LJ, Pawar VS, Panchmatia HR, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology (Baltimore, MD). 2012;55:1344-55
- American Association for the Study of Liver Disease (AASLD). Recommendations for testing, managing, and treating hepatitis C; 2014. http://www.hcvguidelines.org. [Last accessed October 2014]
- Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015;373:2608-17
- Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis Offic Publ Infect Dis Soc Am 2011;52:889-900
- McEwan P, Kim R, Yuan Y. Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl Health Econ Health Policy 2013;11:53-63
- McEwan P, Ward T, Yuan Y, et al. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology (Baltimore, MD) 2013;58:54-64
- McEwan P, Ward T, Chen C-J, et al. Estimating the incidence and prevalence of chronic hepatitis C infection in Taiwan using back projection. Value Health Regional Issues 2014;3:5-11
- Kim RW, McEwan P, Yuan Y. Evaluating optimal treatment outcomes of antiviral therapy in hepatitis C for prior null responders in the era of first generation protease inhibitors. Value Health 2011;14:A283
- McEwan P, Yuan Y, Kim R. Estimating the incidence and prevalence of hepatitis C infection in England using backprojection methods. J Hepatol 2011;54:S461
- McEwan P, Yuan Y, Litalien G, et al. Cost benefit analysis of response guided therapy: dynamic disease Markov modelling for patients with chronic hepatitis C virus (HCV) by fibrosis stages. Berlin, Germany: EASL; 2011
- McEwan P, Ward T, Webster S, et al. Estimating the long-term clinical and economic outcomes of daclatasvir plus asunaprevir in difficult-to-treat Japanese patients chronically infected with hepatitis C genotype 1b. Value Health Regional Issues 2014;3:136-45
- Kamae I, Ward T, Webster S, et al. Investigating treatment strategies to optimise clinical outcomes associated with emerging therapies for HCV. Brisbane, Australia: APASL; 2014
- Kim DY, Han K-H, Jun B, et al. Estimating the cost-effectiveness of one-time screening and treatment for hepatitis C in Korea. PLoS One 2017;12:e0167770
- Chen ZW, Li H, Ren H, et al. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Sci Rep 2016;6:20310
- Rein DB, Wittenborn JS, Smith BD, et al. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis Offic Publ Infect Dis Soc Am 2015;61:157-68
- Martin NK, Vickerman P, Miners A, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology (Baltimore, MD) 2012;55:49-57
- Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology (Baltimore, MD) 2015;61:1127-35